Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice

July 25, 2011

5639220014/?news_id=497 & newsdt=072011 & subspec_id=130

Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine

clinical practice

International Journal of Clinical Practice, 07/20/2011 Clinical Article

Ridruejo E et al. - The entecavir (ETV) monotherapy showed high virological

response rates, a favourable safety profile for NUC-naive HBeAg-positive and

negative patients treated in routine clinical practice.

Methods

• Sixty-nine HBeAg positive and negative NUC naïve chronic HBV patients were

treated with ETV for 110 weeks.

• 63% were HBeAg positive, 16% were cirrhotics, mean HBV-DNA was 7.09 log IU/ml

and mean ALT was 157 IU/ml.

Results

• Sixty-one (88%) patients achieved undetectable DNA, with 46%, 77% and 100%

virological response rates at week 24, 48 and 96 of treatment, respectively.

• Thirty-seven (84%) patients in the HBeAg-positive population achieved

undetectable DNA, with 67% and 100% virological response rates at week 48 and 96

of treatment, respectively.

• Twenty-four (96%) patients in the HBeAg-negative population achieved

undetectable DNA, with 91% and 100% virological response rates at week 48 and 96

of treatment, respectively.

• Twenty-three (53%) patients cleared HBeAg and 19 (44%) patients seroconverted

to antiHBe positive status; seven (10%) patients cleared hepatitis B surface

antigen and five (7%) patients developed antiHBs.

• At the end of the study, 10 patients successfully stopped therapy: nine HBeAg

positive (four developed antiHBs positive) and one HBeAg negative.

• None of the patients had primary non-response.

• ETV resistance was not tested.

• None of the patients developed hepatocellular carcinoma, underwent liver

transplantation or died because of liver-related events.

• No serious adverse events were reported.

Read this article in International Journal of Clinical Practice

Recommended Posts